Evidence map›Paper›PMID 30623084›Full record

ArticleHealth science reports2018

Dialysis-related practice patterns among hemodialysis patients with cancer.

Hiroki Nishiwaki, Shingo Fukuma, Takeshi Hasegawa, Miho Kimachi, Tadao Akizawa, Shunichi Fukuhara

Open access · goldAbstract read
In one paragraph

Article in Health science reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Hiroki NishiwakiCenter for Innovative Research for Communities and Clinical Excellence Fukushima Medical University Fukushima Japan.ORCID 0000-0001-7365-7685
Shingo FukumaCenter for Innovative Research for Communities and Clinical Excellence Fukushima Medical University Fukushima Japan.ORCID 0000-0002-8379-8761
Takeshi HasegawaCenter for Innovative Research for Communities and Clinical Excellence Fukushima Medical University Fukushima Japan.
Miho KimachiInstitute for Health Outcomes and Process Evaluation Research (iHope International) Kyoto Japan.
Tadao AkizawaDivision of Nephrology, Department of Medicine Showa University School of Medicine Tokyo Japan.
Shunichi FukuharaCenter for Innovative Research for Communities and Clinical Excellence Fukushima Medical University Fukushima Japan.
Fukushima Medical University · JPShowa University · JPPE International (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RATIONALE AIMS AND

objectivesWith the achievement of longevity in hemodialysis patients, the risk of comorbid cancer has begun to draw attention. In the present study, we examined dialysis-related practice patterns and compared those patterns by cancer status.

methodsUsing data from the Japan Dialysis Outcomes and Practice Patterns Study phase 4, we evaluated 2153 hemodialysis patients. Baseline cancer status for patients was separated into 3 categories: no cancer, cancer with recent treatment, and cancer without recent treatment. We then assessed variations among hemodialysis patients in dialysis-related practice patterns, including anemia management, management of mineral and bone metabolism disorder, nutritional management, and dialysis treatment, by cancer status.

resultsWe observed both similarities and differences in dialysis-related practice patterns among hemodialysis patients, by cancer status. Hemoglobin levels were largely similar for all cancer statuses, although erythropoiesis stimulating agents dose tended to be higher in hemodialysis patients with recent cancer treatment (multivariable adjusted mean difference of erythropoiesis stimulating agents dose: 5.4 × 10

conclusionAmong long-term facility-based hemodialysis patients with cancer, we detected no statistically significant differences to suggest that cancer status affects hemodialysis practice regarding mineral and bone disorder management, nutritional management, and dialysis treatment. Facility-based hemodialysis patients with recent cancer treatment, however, receive a higher dose of erythropoietin-stimulating agent than those without cancer.

Indexed as

CKD‐MBDerythropoiesishemodialysisneoplasmspractice patternsrenal anemia

Identifiers

PMID30623084
PMCPMC6266572
OpenAlexW2803119329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.